Table 1. Patient characteristics and miRAMM results.

a. sCR patients tested at Day 100 post-ASCT in order of increasing miRAMM M-protein intensity
Age (years)	Sex	FISH risk	Isotype	ISS	Pre-ASCT M-spike, g/dl	Induction response	Maintenance therapy	Days post-ASCT	miRAMM intensity (cps)	PFS (months)
65	M	Intermediate	AK	3	Neg	CR	Yes	103	0	28
49	M	NA	AL	2	Neg	CR	No	105	0	15
67	F	Standard	AL	2	Neg	VGPR	No	98	0	19
61	M	NA	GL	1	0.6	PR	No	102	6700	45a
56	F	NA	AL	1	0.2	VGPR	No	103	10 000	10
44	M	Standard	GL	1	0.6	PR	No	102	10 300	18
59	F	Intermediate	AL	3	0.3	PR	Yes	102	10 900	60a
73	F	NA	AK	1	Neg	VGPR	No	91	24 000	93a
58	F	NA	GK	1	Neg	VGPR	No	100	24 600	38
61	M	High	AK	2	0.3	PR	No	96	32 300	5
67	M	NA	GK/AK	2	Neg	VGPR	Yes	105	32 900	61a
75	F	High	GK	2	0.5	PR	Yes	103	40 000	62a
58	M	Standard	GL	1	2.2	SD	No	102	49 000	60a
71	M	Standard	AK	3	Neg	VGPR	No	99	76 100	23a
64	F	Intermediate	GL	1	0.4	VGPR	No	101	90 400	178
71	M	NA	GK	3	Neg	CR	Yes	106	110 000	75a

b. sCR patients tested at 6–12 months post-ASCT in order of increasing miRAMM M-protein intensity
Age (years)	Sex	FISH risk	Isotype	ISS	Pre-ASCT M-spike, g/dl	Induction response	Maintenance therapy	Days post-ASCT	miRAMM intensity	PFS (months)
49	M	NA	AL	2	Neg	CR	No	364	0	15
71	M	Standard	AK	3	Neg	VGPR	No	323	0	23a
67	M	NA	GK/AK	2	Neg	VGPR	Yes	364	0	61a
58	F	NA	GK	1	Neg	VGPR	No	346	0	38
55	F	NA	AK	2	Neg	PR	No	355	0	66
64	M	NA	GL	2	Neg	CR	Yes	300	0	34
65	M	Standard	AL	1	Neg	CR	No	353	0	39a
69	M	NA	GL	1	0.5	PR	No	246	0	29
51	F	NA	GK	3	Neg	CR	No	307	0	33
56	F	NA	GL	2	1.1	SD	No	194	0	137
62	F	High	AK	1	Neg	VGPR	No	280	800	25
67	F	Standard	AL	2	Neg	VGPR	No	278	1200	19
61	M	NA	GL	1	0.6	PR	No	370	2400	45a
41	M	NA	GK	1	Neg	VGPR	No	173	4400	86
75	F	High	GK	2	0.5	PR	Yes	194	4500	62a
58	M	Standard	GL	1	2.2	SD	No	305	4800	60a
56	F	NA	AL	1	0.2	VGPR	No	297	9500	10
44	M	Standard	GL	1	0.6	PR	No	362	12 100	18
73	F	NA	AK	1	Neg	VGPR	No	350	12 800	93a
41	F	NA	GL	3	Neg	CR	No	179	19 200	75a
66	F	Standard	AL	3	Neg	VGPR	Yes	168	25 700	55a
61	M	High	GK	2	0.9	PR	No	189	26 400	36
50	M	High	GL	1	0.3	PR	Yes	357	28 000	15
66	M	NA	GK	2	0.4	PR	No	189	89 500	31
71	M	Standard	GK	3	Neg	CR	Yes	202	108 000	42

c. sCR patients with miRAMM testing at Day 100 and at 6–12 months post-ASCT in order of decrease rate of changeb of M-protein intensity
Age (years)	Sex	FISH risk	Isotype	ISS	Pre-ASCT M-spike, g/dl	Induction response	Maintenance therapy	Days post-ASCT	Day 100 miRAMM intensity	Days post-ASCT	6–12 Months miRAMM intensity	Rate of change	PFS (months)
49	M	NA	AL	2	Neg	CR	No	105	0	364	0	NA	15
75	F	High	GK	2	0.5	PR	Yes	103	40 000	194	4500	400	62a
71	M	Standard	AK	3	Neg	VGPR	No	99	76 100	323	0	300	23a
58	M	Standard	GL	1	2.2	SD	No	102	49 000	305	4800	200	60a
67	M	NA	GK/AK	2	Neg	VGPR	Yes	105	32 900	364	0	100	61a
58	F	NA	GK	1	Neg	VGPR	No	100	24 600	346	0	100	38
73	F	NA	AK	1	Neg	VGPR	No	91	24 000	350	12 800	40	93a
61	M	NA	GL	1	0.6	PR	No	102	6700	370	2400	20	45a
56	F	NA	AL	1	0.2	VGPR	No	103	10 000	297	9500	0	10
67	F	Standard	AL	2	Neg	VGPR	No	98	0	278	1100	-10	19
44	M	Standard	GL	1	0.6	PR	No	102	10 300	362	12 100	-10	18

Abbreviations: AK, IgA kappa; AL, IgA lambda; ASCT, autologous stem cell transplant; cps, counts per seconds; CR, complete remission; F, female; FISH, fluorescence in situ hybridization; GK, IgG kappa; GL, IgG lambda; ISS, International Staging System; M, male; miRAMM, monoclonal immunoglobulin rapid accurate mass measurement; NA, not applicable; Neg, negative; PFS, progression-free survival; PR, partial remission; sCR, stringent complete response; SD, stable diseas; VGPR, very good partial remission.

^aCensored data, these patients remain disease-free at the time of writing this manuscript.

^bA rate of change in miRAMM M-protein intensity was calculated by dividing the change in miRAMM intensity by the time interval between measurements in days.